The medical device maker has completed more than 40 acquisitions in recent years, helping turn it into one of the state’s ...

Boston Scientific's strong history, margins, and pipeline make it a buy despite other analysts' Hold rating, with 15% growth ...

Boston Scientific BSX is gaining traction in the international markets. New regulatory approvals and accretive acquisitions ...

Continuing GLP-1 receptor agonist medications when undergoing an endoscopic procedure appeared safe in a meta-analysis.

The MedSurg division, which includes endoscopy, urology, and neuromodulation devices, had a 10% revenue rise to $1.48 billion. Boston Scientific Lowers FY EPS Outlook, Raises Adjusted EPS The ...

Endoscopy net sales were $678 million ... For the fourth quarter of 2024, Boston Scientific expects EPS to range between $0.64 and $0.66, compared to analyst expectations of $0.64.

Boston Scientific is keeping the ball rolling in ... as well as 10.3% growth among medical surgical tools—including endoscopy, urology and neuromodulation—that totaled $1.479 billion.